Creates provisions relating to cost-sharing under health benefit plans
Summary
HB 1681 creates a new section in Missouri insurance law governing cost-sharing under health benefit plans. The bill requires health carriers and pharmacy benefits managers to count amounts paid by or on behalf of an enrollee toward out-of-pocket maximums and other cost-sharing requirements when the medication has no available generic substitute. It also bars carriers and PBMs from structuring cost-sharing or benefit design around the existence of a cost-sharing assistance program for such medications.
The bill includes special rules for health savings account-qualified high deductible health plans. If applying the new cost-sharing rule would conflict with federal HSA rules, the requirement would apply only after the enrollee meets the federal minimum deductible, except for preventive care, where it would apply regardless of deductible status. The bill also clarifies that it does not prohibit step therapy and does not apply to health plans covered by the federal Labor Management Relations Act. The provisions would take effect for plans entered into, amended, extended, or renewed on or after August 28, 2026.
Impact
HB 1681 would amend Chapter 376, RSMo, by adding section 376.448 and imposing new requirements on health carriers and pharmacy benefits managers in the administration of prescription drug cost-sharing. It would affect how insurers calculate out-of-pocket maximums and cost-sharing obligations for drugs without generic alternatives, and it would limit plan designs that account for patient assistance programs in those cases. The bill would not apply to certain collectively bargained plans governed by federal labor law, and it would preserve existing step therapy authority under Missouri law.
Sentiment
No committee transcript or vote record was provided, so there is no direct evidence of debate or recorded support/opposition in the materials supplied. Based on the bill text alone, the measure appears consumer-protective and aimed at reducing enrollee cost burdens for certain high-cost medications, suggesting likely support from patient advocates and some opposition or concern from insurers and pharmacy benefits managers over added plan costs and benefit-design restrictions.
Contention
The main points of contention are likely to be the financial and administrative impact on health carriers and pharmacy benefits managers, especially the requirement to credit payments for drugs without generic substitutes toward deductibles and out-of-pocket limits. Another likely issue is the prohibition on varying cost-sharing based on the availability of patient assistance programs, which may be viewed as limiting insurer flexibility. The bill also contains a federal preemption/HSA carveout and an exclusion for LMRA-covered plans, indicating sensitivity to federal law constraints and potential objections from employer-sponsored plan stakeholders.